| 001 | 137828 | ||
| 005 | 20210129212117.0 | ||
| 024 | 7 | _ | |a 10.1016/j.nucmedbio.2013.09.001 |2 doi |
| 024 | 7 | _ | |a WOS:000328009300001 |2 WOS |
| 037 | _ | _ | |a FZJ-2013-04138 |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Kroll, Tina |0 P:(DE-Juel1)131691 |b 0 |u fzj |e Corresponding author |
| 245 | _ | _ | |a [18F]Altanserin and small animal PET: Impact of multidrug efflux transporters on ligand brain uptake and subsequent quantification of 5-HT2A receptor densities in the rat brain |
| 260 | _ | _ | |a Amsterdam [u.a.] |c 2014 |b Elsevier Science |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1392903127_23713 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a article |2 DRIVER |
| 500 | _ | _ | |3 POF3_Assignment on 2016-02-29 |
| 520 | _ | _ | |a The selective 5-hydroxytryptamine type 2a receptor (5-HT2AR) radiotracer [18F]altanserin is a promising ligand for in vivo brain imaging in rodents. However, [18F]altanserin is a substrate of P-glycoprotein (P-gp) in rats. Its applicability might therefore be constrained by both a differential expression of P-gp under pathological conditions, e.g. epilepsy, and its relatively low cerebral uptake. The aim of the present study was therefore twofold: (i) to investigate whether inhibition of multidrug transporters (MDT) is suitable to enhance the cerebral uptake of [18F]altanserin in vivo and (ii) to test different pharmacokinetic, particularly reference tissue-based models for exact quantification of 5-HT2AR densities in the rat brain. |
| 536 | _ | _ | |a 333 - Pathophysiological Mechanisms of Neurological and Psychiatric Diseases (POF2-333) |0 G:(DE-HGF)POF2-333 |c POF2-333 |x 0 |f POF II |
| 700 | 1 | _ | |a Matusch, Andreas |0 P:(DE-Juel1)138474 |b 1 |u fzj |
| 700 | 1 | _ | |a Celik, A. Avdo |0 P:(DE-Juel1)131756 |b 2 |u fzj |
| 700 | 1 | _ | |a Wedekind, Franziska |0 P:(DE-Juel1)131711 |b 3 |u fzj |
| 700 | 1 | _ | |a Weißhaupt, Angela |0 P:(DE-Juel1)131712 |b 4 |u fzj |
| 700 | 1 | _ | |a Beer, Simone |0 P:(DE-Juel1)133864 |b 5 |u fzj |
| 700 | 1 | _ | |a Bauer, Andreas |0 P:(DE-Juel1)131672 |b 6 |u fzj |
| 773 | _ | _ | |a 10.1016/j.nucmedbio.2013.09.001 |p 1-9 |n 1 |0 PERI:(DE-600)1498538-x |t Nuclear medicine and biology |v 41 |x 1872-9614 |
| 856 | 4 | _ | |u https://juser.fz-juelich.de/record/137828/files/FZJ-2013-04138.pdf |z Published final document. |y Restricted |
| 909 | C | O | |o oai:juser.fz-juelich.de:137828 |p VDB |
| 910 | 1 | _ | |a Forschungszentrum Jülich GmbH |0 I:(DE-588b)5008462-8 |k FZJ |b 0 |6 P:(DE-Juel1)131691 |
| 910 | 1 | _ | |a Forschungszentrum Jülich GmbH |0 I:(DE-588b)5008462-8 |k FZJ |b 1 |6 P:(DE-Juel1)138474 |
| 910 | 1 | _ | |a Forschungszentrum Jülich GmbH |0 I:(DE-588b)5008462-8 |k FZJ |b 2 |6 P:(DE-Juel1)131756 |
| 910 | 1 | _ | |a Forschungszentrum Jülich GmbH |0 I:(DE-588b)5008462-8 |k FZJ |b 3 |6 P:(DE-Juel1)131711 |
| 910 | 1 | _ | |a Forschungszentrum Jülich GmbH |0 I:(DE-588b)5008462-8 |k FZJ |b 4 |6 P:(DE-Juel1)131712 |
| 910 | 1 | _ | |a Zentralinstitut für Elektronik |0 I:(DE-Juel1)ZEA-2-20090406 |k ZEA-2 |b 5 |6 P:(DE-Juel1)133864 |
| 910 | 1 | _ | |a Molekulare Organisation des Gehirns |0 I:(DE-Juel1)INM-2-20090406 |k INM-2 |b 5 |6 P:(DE-Juel1)133864 |
| 910 | 1 | _ | |a Zentralinstitut für Elektronik |0 I:(DE-Juel1)ZEA-2-20090406 |k ZEA-2 |b 5 |6 P:(DE-Juel1)133864 |
| 910 | 1 | _ | |a Forschungszentrum Jülich GmbH |0 I:(DE-588b)5008462-8 |k FZJ |b 5 |6 P:(DE-Juel1)133864 |
| 910 | 1 | _ | |a Forschungszentrum Jülich GmbH |0 I:(DE-588b)5008462-8 |k FZJ |b 6 |6 P:(DE-Juel1)131672 |
| 913 | 2 | _ | |a DE-HGF |b Key Technologies |l Decoding the Human Brain |1 G:(DE-HGF)POF3-570 |0 G:(DE-HGF)POF3-579H |2 G:(DE-HGF)POF3-500 |v Addenda |x 0 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Funktion und Dysfunktion des Nervensystems |1 G:(DE-HGF)POF2-330 |0 G:(DE-HGF)POF2-333 |2 G:(DE-HGF)POF2-300 |v Pathophysiological Mechanisms of Neurological and Psychiatric Diseases |x 0 |4 G:(DE-HGF)POF |3 G:(DE-HGF)POF2 |
| 914 | 1 | _ | |y 2014 |
| 915 | _ | _ | |a Peer review unknown |0 StatID:(DE-HGF)0040 |2 StatID |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0110 |2 StatID |b Science Citation Index |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Thomson Reuters Master Journal List |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0310 |2 StatID |b NCBI Molecular Biology Database |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |
| 920 | 1 | _ | |0 I:(DE-Juel1)INM-2-20090406 |k INM-2 |l Molekulare Organisation des Gehirns |x 0 |
| 920 | 1 | _ | |0 I:(DE-Juel1)INM-4-20090406 |k INM-4 |l Physik der Medizinischen Bildgebung |x 1 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a I:(DE-Juel1)INM-2-20090406 |
| 980 | _ | _ | |a I:(DE-Juel1)INM-4-20090406 |
| 981 | _ | _ | |a I:(DE-Juel1)INM-4-20090406 |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|
guest ::